gms | German Medical Science

66th Annual Meeting of the German Society of Neurosurgery (DGNC)
Friendship Meeting with the Italian Society of Neurosurgery (SINch)

German Society of Neurosurgery (DGNC)

7 - 10 June 2015, Karlsruhe

Article

Send article

Is there a place for [18F]-FET PET in MRI-suspected recurrences of radiosurgically treated brain metastases?

Meeting Abstract

Search Medline for

  • Alexander Romagna - Neurochirurgische Klinik und Poliklinik
  • Nathalie Jansen - Klinik und Poliklinik für Nuklearmedizin
  • Jürgen Lutz - Abteilung für Neuroradiologie
  • Jörg-Christian Tonn - Neurochirurgische Klinik und Poliklinik
  • Silke Nachbichler - Klinik für Strahlentherapie und Radioonkologie, Klinikum der Ludwig-Maximilians-Universität München, Campus Großhadern
  • Friedrich-Wilhelm Kreth - Neurochirurgische Klinik und Poliklinik

Deutsche Gesellschaft für Neurochirurgie. 66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC). Karlsruhe, 07.-10.06.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. DocP 159

doi: 10.3205/15dgnc557, urn:nbn:de:0183-15dgnc5577

Published: June 2, 2015

© 2015 Romagna et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: After radiosurgery of brain metastases, the MRI-based differentiation between tumor recurrence and radiation-induced lesions is challenging. In this context, the place of [18F] Fluoroethyltyrosine positron emission tomography ([18F]-FET PET) is poorly defined. In the current series, static and dynamic PET findings were described in correlation with both histological findings and follow-up evaluation.

Method: Patients with MRI-suspected tumor recurrences after previously performed radiosurgical treatment were included (03/2006-11/2013). Radiosurgery alone (median dose 20 Gy) or in combination with whole brain radiotherapy (median dose 30 Gy) was applied in 6 and 5 patients, respectively. MRI criteria for a recurrence were i) the appearance of a new contrast enhancing area after previously observed complete response or ii) an increase of the enhancing area after previously observed partial response/ stable disease. [18F]-FET PET analysis was done in all patients and included the assessment of both maximum standardized uptake value to background activity (SUVmax/BG) and dynamic analysis of intratumoral 18F-FET uptake over time (increasing vs. decreasing time-activity curves). PET-guided stereotactic biopsy was performed in all patients. Follow-up evaluation was done in three months intervals. Informed consent was obtained from all patients.

Results: Biopsy revealed a tumor recurrence in 7 patients and a reactive lesion in 4 patients (false positive rate of MRI: 37%). All patients with a biopsy-proven tumor recurrence exhibited a SUVmax/BG > 2 in combination with decreasing time activity curves (TAC). Two out of 4 patients with proven radiogenic lesions showed a SUVmax/BG < 2 in combination with increasing TAC, whereas the other two displayed PET findings not distinguishable from that of the recurrence group. In the former two patients, regressive lesions were seen over time (median follow-up 12 months), whereas in the latter two patients tumor recurrence occurred 4 and 7 months after biopsy.

Conclusions: Conventional MRI is notoriously inaccurate in the differential diagnosis of radiosurgically treated brain metastases. SUVmax/BG values > 2 in combination with decreasing TAC are highly suspicious for a tumor recurrence. Whether increased SUVmax/BG values can predict early recurrence even in patients with biopsy-proven radiogenic lesions deserves further evaluation. At the moment, close follow-up evaluation is recommended for these patients.